Patents by Inventor Fatima-Soraya TALEB

Fatima-Soraya TALEB has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and pharmaceutical compositions for the treatment of obesity
    Patent number: 11752131
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of obesity. In particular, the present invention relates to a method of treating obesity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an indoleamine 2-3 dioxygenase (IDO) inhibitor.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: September 12, 2023
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DESCARTES
    Inventors: Fatima-Soraya Taleb, Ziad Mallat, Alain Tedgui
  • METHODS FOR PROGNOSING AND TREATING METABOLIC DISEASES
    Publication number: 20210000889
    Abstract: The present invention relates to methods for prognosing and treating metabolic diseases. The inventors demonstrated the association of obesity with the increase of intestinal IDO activity, which shifts tryptophan (Trp) metabolism from indole derivative but also IL-22 production towards kynurenine (Kyn) production. The inventors showed that the rewiring of Tip metabolism is possible towards a microbiota-dependent production of IL-22.
    Type: Application
    Filed: February 28, 2019
    Publication date: January 7, 2021
    Inventors: Fatima-Soraya TALEB, Harry SOKOL, Ludivine LAURANS
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OBESITY
    Publication number: 20180369198
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of obesity. In particular, the present invention relates to a method of treating obesity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an indoleamine 2-3 dioxygenase (IDO) inhibitor.
    Type: Application
    Filed: February 17, 2017
    Publication date: December 27, 2018
    Inventors: Fatima-Soraya TALEB, Ziad MALLAT, Alain TEDGUI